Biotech Earnings Preview: Voyager and Zevra Q4 2025 Results in Focus

The Q4 2025 earnings season arrives at a defining moment for the biotechnology sector, with Voyager Technologies and Zevra Therapeutics serving as key indicators for two distinct but related high-growth areas: next-generation gene therapy delivery and the commercialization of orphan drugs. As the industry moves past the volatility of previous years, the focus for the March 2026 reporting period has shifted from pure clinical potential to tangible execution and fiscal discipline. For Voyager, this means proving the scalability of its TRACER capsid platform, while for Zevra, it involves demonstrating that a specialized sales force can drive meaningful adoption in the rare disease space.

Voyager Technologies remains one of the most watched entities in the genomic medicine space due to its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) discovery platform. The central challenge in gene therapy has long been the delivery problem—getting genetic payloads to the right cells without triggering systemic toxicity. Voyager’s Q4 results are expected to provide updates on how its engineered AAV capsids are performing in CNS-targeted programs, particularly in Alzheimer’s disease and ALS. The company’s financial health is bolstered by its strategic collaborations with Novartis and Neurocrine Biosciences, which have provided significant upfront payments and potential for bio-buck milestones. Analysts will be looking for confirmation that these partnerships are progressing toward clinical milestones, as these validations are essential for Voyager’s valuation as a platform-based biotech.

“

The company’s financial health is bolstered by its strategic collaborations with Novartis and Neurocrine Biosciences, which have provided significant upfront payments and potential for bio-buck milestones.

Zevra Therapeutics, conversely, is navigating the commercial chasm that often swallows mid-cap biotechs. The Q4 2025 report will be a litmus test for the company’s ability to transition from a R&D-heavy organization to a profitable commercial enterprise. The spotlight is firmly on arimoclomol, Zevra’s treatment for Niemann-Pick disease type C (NPC). Following its regulatory path, the market is now looking for evidence of patient enrollment and payer coverage. Additionally, the performance of Azstarys, a treatment for ADHD, continues to be a vital source of royalty revenue that helps offset the high costs of launching a rare disease drug. The ability of Zevra to manage its cash burn while scaling its commercial infrastructure will be the primary focus for institutional investors during the earnings call.